Jefferies on Gilead Sciences (GILD): 'Competitor Dato surprise setback in breast cancer, new incremental (+) for GILD'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $95.00 price target on Gilead Sciences (NASDAQ: GILD)The analyst comments "Competitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
